Bluebird Bio Inc (BLUE) 37.36 $BLUE
Will Quest Diagnostics (DGX) Surprise Earnings in Q3? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Oct 21, 2:30PM CDT
Quest Diagnostics Inc. (DGX) is scheduled to report its third-quarter 2014 results before the opening bell on Oct 23.
BLUE: 37.36 (+0.54), MDVN: 96.97 (+1.99), PACB: 5.56 (unch), DGX: 61.12 (+1.47)
Will Zimmer (ZMH) Miss Earnings Estimates this Quarter? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Oct 21, 2:10PM CDT
Zimmer Holdings Inc. (ZMH) is scheduled to report its third-quarter 2014 results before the opening bell on Oct 23.
BLUE: 37.36 (+0.54), MDVN: 96.97 (+1.99), ZMH: 101.32 (+2.13), PACB: 5.56 (unch)
Will Boston Scientific (BSX) Surprise this Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Oct 20, 2:20PM CDT
Boston Scientific Corporation (BSX) is scheduled to report its third-quarter 2014 results before the opening bell on Oct 22.
BLUE: 37.36 (+0.54), MDVN: 96.97 (+1.99), BSX: 12.03 (+0.42), PACB: 5.56 (unch)
bluebird bio Announces First Patient with Sickle Cell Disease Transplanted with LentiGlobin Gene Therapy
Business Wire - Tue Oct 14, 6:00AM CDT
bluebird bio, Inc. (Nasdaq: BLUE) a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic and orphan diseases, today announced that the first subject with severe sickle cell disease has undergone infusion with bluebird bio's LentiGlobin BB305 drug product in an autologous hematopoietic stem cell transplantation. This patient is enrolled in the HGB-205 Study being conducted in Paris, France. bluebird has also opened a separate US-based trial (HGB-206) in the United States for the treatment of up to 8 severe sickle cell disease patients with the company's LentiGlobin BB305 drug product.
BLUE: 37.36 (+0.54)
Insider Trading Alert - BLUE, NVAX And SNCR Traded By Insiders
at The Street - Mon Oct 06, 9:15AM CDT
Stocks with insider trader activity include BLUE, NVAX and SNCR
BLUE: 37.36 (+0.54), SNCR: 45.56 (+0.89), NVAX: 4.99 (-0.02)
Acceleron Hit Over Competitive Concerns, But Investors Overlook Rest of Pipeline
at The Street - Thu Oct 02, 8:21AM CDT
An Acceleron update in December could reignite investor interest in the stock.
BLUE: 37.36 (+0.54), XLRN: 29.13 (-0.03)
Global Gene Therapy Market Outlook 2018
M2 - Wed Sep 17, 5:51AM CDT
Research and Markets (http://www.researchandmarkets.com/research/bqlkd5/global_gene) has announced the addition of the "Global Gene Therapy Market Outlook 2018" report to their offering. Gene therapy is the treatment of a disease by replacing, altering, or supplementing a gene that is absent or abnormal and whose absence or abnormality is causing the disease. It has evolved as one of the most sought after research objectives for difficult to cure' diseases. The gene therapy market, presenting a few marketable products and being nascent in terms of revenue generation, holds tremendous growth potential. As per a new estimation carried out in our latest study, the global gene therapy industry has the potential to become a multi-million dollar industry by the end of 2018, as new products, especially those in the advanced stage of clinical studies or with pending approvals, may enter the market to boost the growth. Primarily, the gene therapy market is dominated by oncology applications with several companies and academic institutions focusing on novel and difficult to treat' cancers. Other therapeutic areas seeing developments in gene therapy include cardiac conditions, inherited blindness, genetic disorders and neurological diseases. An effective analysis of the key therapeutic areas has been included in the report. Also, a brief overview of the key geographies in the gene therapy market and the regulatory scenario governing the industry has been included to present a balanced outlook. Unlike other regions globally, the United States continues to have the maximum number of clinical trials in the gene therapy segment. This shows the country's potential to become a leader in gene therapy in the coming years. Key Topics Covered: 1. Analyst View 2. Research Methodology 3. Gene Therapy - An Introduction Classification of Gene Therapy Techniques Physical Methods of Gene Transfer - Electroporation - Hydrodynamic - Microinjection - Particle Bombardment - Ultrasound-mediated Transfection Vectors for Gene Therapy - Adenoviral Vectors - Adeno-associated Virus Vectors - Retroviral Vectors - Lentiviral Vectors - Plasmid DNA 4. Industry Trends and Drivers Industry Trends - Gene Silencing: Gaining Momentum - Advanced Therapies: Combining Gene Therapy and Stem Cell Technology - Immunodeficiency Syndromes: The Focus of Gene Therapy - Nanotechnology: Empowering Gene Therapy - Gene Therapy: A New Hope to Treat Blindness - Gene Therapy: Potential Cure for Cancer Market Drivers - Failure of Conventional Therapies to Treat Cancers - Entry of Gene Therapies in Developed Nations - Rising Incidence of Chronic and Life Threatening Diseases - Growing Interest of Venture Capital Firms 5. Market Restraints - High Cost of Treatment - Stringent Regulatory Laws & Safety Concerns - Pitfalls in Current Technique 6. Gene Therapy Market Outlook - Oncology - Infectious Diseases - Genetic Disorders - Cardiovascular Disorders - Diabetes Mellitus - Neurological Disorders 7. Gene Therapy Market - Regulatory Landscape 8. Advanced Gene Therapy Drugs - Collategene - Allovectin-7 - Generx - Glybera 9. Mergers and Acquisitions - Sangamo BioSciences to Acquire Gene Therapy Company Ceregene. - Baxter to Acquire Chatham Therapeutics - Bluebird Bio Acquired Privately Held Gene-Editing Company - Miltenyi Acquired Gene Therapy Assets from Lentigen - Dutch Player UniQure to Acquire InoCard GmbH for CHF Therapy. 10. Key Players Analysis (Business Description, Clinical Pipeline, Recent Developments, Strengths & Weaknesses, Key People) - Spark Therapeutics, LLC - ViroMed Co. Ltd. dba VM BioPharma - Advantagene Inc - Bluebird Bio - Sanofi - Genzyme - A Sanofi Company - Kolon Life Science - Vical Inc - Oxford BioMedica - Genethon For more information visit http://www.researchandmarkets.com/research/bq...lobal_gene
BLUE: 37.36 (+0.54), VICL: 1.20 (+0.01), SGMO: 10.52 (-0.18)
Primp and Blow, a Blow Dry Bar, Aims Higher With New Location
PRWeb - Tue Sep 16, 6:21AM CDT
Primp and Blow, a blow dry bar, is set to open its fourth location on High Street (formally CityNorth) in Northeast Phoenix this week, joining restaurants and retail stores including Blue Martini, Modern Margarita and 42 Saint, The Offices on High Street, which will soon include Sprouts Farmers Market's new corporate headquarters and The Residences on High Street's luxury apartment rentals.
BLUE: 37.36 (+0.54)
Insider Trading Alert - BLUE, BHI And HCP Traded By Insiders
at The Street - Thu Sep 04, 10:00AM CDT
Stocks with insider trader activity include BLUE, BHI and HCP
BLUE: 37.36 (+0.54), HCP: 42.58 (-0.33), BHI: 54.23 (+1.58)
bluebird bio to Present at Morgan Stanley Global Health Care Conference
Business Wire - Tue Sep 02, 4:30PM CDT
bluebird bio, Inc. (Nasdaq: BLUE) announces that management will present at the Morgan Stanley Global Healthcare Conference on Wednesday, September 10, 2014 at 2.30 PM ( EDT) at the Grand Hyatt New York Hotel, New York, NY.
BLUE: 37.36 (+0.54), MS: 34.06 (+0.74)
Bluebird Bio (BLUE) Stock: Weak On High Volume Today
at The Street - Tue Sep 02, 9:01AM CDT
Trade-Ideas LLC identified bluebird bio (BLUE) as a weak on high relative volume candidate
BLUE: 37.36 (+0.54)
Critical Alerts For bluebird bio Inc., United Therapeutics Corporation, Mattel Inc, Ulta Salon Cosmetics & Fragrance Inc. and Applied Materials Inc. Released By InvestorsObserver
PR Newswire - Tue Sep 02, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for BLUE, UTHR, MAT, ULTA and AMAT.
BLUE: 37.36 (+0.54), MAT: 29.53 (+0.06), AMAT: 20.78 (+0.71), UTHR: 127.61 (+1.15), ULTA: 118.97 (-0.90)
5 Stocks Triggering Big Breakout Trades
at The Street - Mon Aug 18, 10:12AM CDT
These stocks look poised to break out and trade higher from current levels.
BLUE: 37.36 (+0.54), TTPH: 23.89 (+0.34), AMRS: 3.26 (-0.20), ZSPH: 32.67 (-1.33), SCTY: 55.73 (+1.81), ALXN: 174.48 (+6.28)
bluebird bio Reports Fiscal Second Quarter 2014 Financial Results
Business Wire - Tue Aug 12, 4:00PM CDT
bluebird bio, Inc. (Nasdaq: BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic and orphan diseases, today reported financial results and operational highlights for the quarter ended June 30, 2014.
BLUE: 37.36 (+0.54), GE: 25.45 (+0.42)
bluebird bio to Present at Two Upcoming Health Care Conferences
Business Wire - Tue Aug 05, 3:06PM CDT
bluebird bio, Inc. (Nasdaq: BLUE) announces that management will present at the Wedbush Life Science Conference on Wednesday, August 13, 2014 at 12.40 PM (EDT) at the Parker Meridian Hotel, New York, NY. Management will also present at the Canaccord Genuity Growth Conference on Thursday, August 14, 2014 at 2:00 PM (EDT) at the InterContinental Hotel, Boston, MA.
BLUE: 37.36 (+0.54)
5 Stocks Ready for Breakouts
at The Street - Mon Aug 04, 9:14AM CDT
These stocks are within range of triggering breakout trades.
BLUE: 37.36 (+0.54), TSLA: 235.34 (+4.87), ZPIN: 12.78 (-0.07), OVTI: 26.25 (-0.55), CDXS: 2.30 (+0.01), ATRO: 44.80 (+0.29)
Acquisition Agreements, Rejected Acquisition Tender Offers, Appointment, and Technical Updates - Research Reports on Pfizer, Gentiva, bluebird bio, Agios and AcelRx
PR Newswire - Wed Jul 23, 7:30AM CDT
Today, Analysts Review released its research reports regarding Pfizer Inc. (NYSE: PFE), Gentiva Health Services Inc. (NASDAQ: GTIV), bluebird bio, Inc. (NASDAQ: BLUE), Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) and AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/5013-100free.
ACRX: 6.85 (-0.05), BLUE: 37.36 (+0.54), PFE: 28.28 (+0.35), AGIO: 72.90 (+4.65), GTIV: 19.39 (unch)
3 Biotech Stocks Breaking Out on Big Volume
at The Street - Mon Jul 21, 8:10AM CDT
These biotech stocks rising on unusual volume are within range of triggering breakout trades.
BLUE: 37.36 (+0.54), RARE: 47.20 (+1.28), IMGN: 8.84 (-0.62)
bluebird bio, Inc. (BLUE) in Focus: Stock Surges 10.24% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Jul 21, 7:44AM CDT
bluebird bio, Inc. (BLUE) was a big mover last session, as the company saw its shares surge over 10% on the day.
BLUE: 37.36 (+0.54), BIIB: 326.77 (+15.36), BMRN: 74.71 (+3.71), ALXN: 174.48 (+6.28)
Buying Bluebird's Blockbuster Potential at a Discount
at The Street - Thu Jul 17, 9:33AM CDT
It's not often an investor gets the opportunity to buy a biotech stock with two blockbuster indications in the pipeline and major catalysts only months away at such a discount.
BLUE: 37.36 (+0.54)
Will Quest Diagnostics (DGX) Surprise Earnings in Q3? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Oct 21, 2:30PM CDT
Quest Diagnostics Inc. (DGX) is scheduled to report its third-quarter 2014 results before the opening bell on Oct 23.
BLUE: 37.36 (+0.54), MDVN: 96.97 (+1.99), PACB: 5.56 (unch), DGX: 61.12 (+1.47)
Will Zimmer (ZMH) Miss Earnings Estimates this Quarter? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Oct 21, 2:10PM CDT
Zimmer Holdings Inc. (ZMH) is scheduled to report its third-quarter 2014 results before the opening bell on Oct 23.
BLUE: 37.36 (+0.54), MDVN: 96.97 (+1.99), ZMH: 101.32 (+2.13), PACB: 5.56 (unch)
Will Boston Scientific (BSX) Surprise this Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Oct 20, 2:20PM CDT
Boston Scientific Corporation (BSX) is scheduled to report its third-quarter 2014 results before the opening bell on Oct 22.
BLUE: 37.36 (+0.54), MDVN: 96.97 (+1.99), BSX: 12.03 (+0.42), PACB: 5.56 (unch)
bluebird bio Announces First Patient with Sickle Cell Disease Transplanted with LentiGlobin Gene Therapy
Business Wire - Tue Oct 14, 6:00AM CDT
bluebird bio, Inc. (Nasdaq: BLUE) a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic and orphan diseases, today announced that the first subject with severe sickle cell disease has undergone infusion with bluebird bio's LentiGlobin BB305 drug product in an autologous hematopoietic stem cell transplantation. This patient is enrolled in the HGB-205 Study being conducted in Paris, France. bluebird has also opened a separate US-based trial (HGB-206) in the United States for the treatment of up to 8 severe sickle cell disease patients with the company's LentiGlobin BB305 drug product.
BLUE: 37.36 (+0.54)
Insider Trading Alert - BLUE, NVAX And SNCR Traded By Insiders
at The Street - Mon Oct 06, 9:15AM CDT
Stocks with insider trader activity include BLUE, NVAX and SNCR
BLUE: 37.36 (+0.54), SNCR: 45.56 (+0.89), NVAX: 4.99 (-0.02)
Acceleron Hit Over Competitive Concerns, But Investors Overlook Rest of Pipeline
at The Street - Thu Oct 02, 8:21AM CDT
An Acceleron update in December could reignite investor interest in the stock.
BLUE: 37.36 (+0.54), XLRN: 29.13 (-0.03)
Global Gene Therapy Market Outlook 2018
M2 - Wed Sep 17, 5:51AM CDT
Research and Markets (http://www.researchandmarkets.com/research/bqlkd5/global_gene) has announced the addition of the "Global Gene Therapy Market Outlook 2018" report to their offering. Gene therapy is the treatment of a disease by replacing, altering, or supplementing a gene that is absent or abnormal and whose absence or abnormality is causing the disease. It has evolved as one of the most sought after research objectives for difficult to cure' diseases. The gene therapy market, presenting a few marketable products and being nascent in terms of revenue generation, holds tremendous growth potential. As per a new estimation carried out in our latest study, the global gene therapy industry has the potential to become a multi-million dollar industry by the end of 2018, as new products, especially those in the advanced stage of clinical studies or with pending approvals, may enter the market to boost the growth. Primarily, the gene therapy market is dominated by oncology applications with several companies and academic institutions focusing on novel and difficult to treat' cancers. Other therapeutic areas seeing developments in gene therapy include cardiac conditions, inherited blindness, genetic disorders and neurological diseases. An effective analysis of the key therapeutic areas has been included in the report. Also, a brief overview of the key geographies in the gene therapy market and the regulatory scenario governing the industry has been included to present a balanced outlook. Unlike other regions globally, the United States continues to have the maximum number of clinical trials in the gene therapy segment. This shows the country's potential to become a leader in gene therapy in the coming years. Key Topics Covered: 1. Analyst View 2. Research Methodology 3. Gene Therapy - An Introduction Classification of Gene Therapy Techniques Physical Methods of Gene Transfer - Electroporation - Hydrodynamic - Microinjection - Particle Bombardment - Ultrasound-mediated Transfection Vectors for Gene Therapy - Adenoviral Vectors - Adeno-associated Virus Vectors - Retroviral Vectors - Lentiviral Vectors - Plasmid DNA 4. Industry Trends and Drivers Industry Trends - Gene Silencing: Gaining Momentum - Advanced Therapies: Combining Gene Therapy and Stem Cell Technology - Immunodeficiency Syndromes: The Focus of Gene Therapy - Nanotechnology: Empowering Gene Therapy - Gene Therapy: A New Hope to Treat Blindness - Gene Therapy: Potential Cure for Cancer Market Drivers - Failure of Conventional Therapies to Treat Cancers - Entry of Gene Therapies in Developed Nations - Rising Incidence of Chronic and Life Threatening Diseases - Growing Interest of Venture Capital Firms 5. Market Restraints - High Cost of Treatment - Stringent Regulatory Laws & Safety Concerns - Pitfalls in Current Technique 6. Gene Therapy Market Outlook - Oncology - Infectious Diseases - Genetic Disorders - Cardiovascular Disorders - Diabetes Mellitus - Neurological Disorders 7. Gene Therapy Market - Regulatory Landscape 8. Advanced Gene Therapy Drugs - Collategene - Allovectin-7 - Generx - Glybera 9. Mergers and Acquisitions - Sangamo BioSciences to Acquire Gene Therapy Company Ceregene. - Baxter to Acquire Chatham Therapeutics - Bluebird Bio Acquired Privately Held Gene-Editing Company - Miltenyi Acquired Gene Therapy Assets from Lentigen - Dutch Player UniQure to Acquire InoCard GmbH for CHF Therapy. 10. Key Players Analysis (Business Description, Clinical Pipeline, Recent Developments, Strengths & Weaknesses, Key People) - Spark Therapeutics, LLC - ViroMed Co. Ltd. dba VM BioPharma - Advantagene Inc - Bluebird Bio - Sanofi - Genzyme - A Sanofi Company - Kolon Life Science - Vical Inc - Oxford BioMedica - Genethon For more information visit http://www.researchandmarkets.com/research/bq...lobal_gene
BLUE: 37.36 (+0.54), VICL: 1.20 (+0.01), SGMO: 10.52 (-0.18)
Primp and Blow, a Blow Dry Bar, Aims Higher With New Location
PRWeb - Tue Sep 16, 6:21AM CDT
Primp and Blow, a blow dry bar, is set to open its fourth location on High Street (formally CityNorth) in Northeast Phoenix this week, joining restaurants and retail stores including Blue Martini, Modern Margarita and 42 Saint, The Offices on High Street, which will soon include Sprouts Farmers Market's new corporate headquarters and The Residences on High Street's luxury apartment rentals.
BLUE: 37.36 (+0.54)
Insider Trading Alert - BLUE, BHI And HCP Traded By Insiders
at The Street - Thu Sep 04, 10:00AM CDT
Stocks with insider trader activity include BLUE, BHI and HCP
BLUE: 37.36 (+0.54), HCP: 42.58 (-0.33), BHI: 54.23 (+1.58)
bluebird bio to Present at Morgan Stanley Global Health Care Conference
Business Wire - Tue Sep 02, 4:30PM CDT
bluebird bio, Inc. (Nasdaq: BLUE) announces that management will present at the Morgan Stanley Global Healthcare Conference on Wednesday, September 10, 2014 at 2.30 PM ( EDT) at the Grand Hyatt New York Hotel, New York, NY.
BLUE: 37.36 (+0.54), MS: 34.06 (+0.74)
Bluebird Bio (BLUE) Stock: Weak On High Volume Today
at The Street - Tue Sep 02, 9:01AM CDT
Trade-Ideas LLC identified bluebird bio (BLUE) as a weak on high relative volume candidate
BLUE: 37.36 (+0.54)
Critical Alerts For bluebird bio Inc., United Therapeutics Corporation, Mattel Inc, Ulta Salon Cosmetics & Fragrance Inc. and Applied Materials Inc. Released By InvestorsObserver
PR Newswire - Tue Sep 02, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for BLUE, UTHR, MAT, ULTA and AMAT.
BLUE: 37.36 (+0.54), MAT: 29.53 (+0.06), AMAT: 20.78 (+0.71), UTHR: 127.61 (+1.15), ULTA: 118.97 (-0.90)
5 Stocks Triggering Big Breakout Trades
at The Street - Mon Aug 18, 10:12AM CDT
These stocks look poised to break out and trade higher from current levels.
BLUE: 37.36 (+0.54), TTPH: 23.89 (+0.34), AMRS: 3.26 (-0.20), ZSPH: 32.67 (-1.33), SCTY: 55.73 (+1.81), ALXN: 174.48 (+6.28)
bluebird bio Reports Fiscal Second Quarter 2014 Financial Results
Business Wire - Tue Aug 12, 4:00PM CDT
bluebird bio, Inc. (Nasdaq: BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic and orphan diseases, today reported financial results and operational highlights for the quarter ended June 30, 2014.
BLUE: 37.36 (+0.54), GE: 25.45 (+0.42)
bluebird bio to Present at Two Upcoming Health Care Conferences
Business Wire - Tue Aug 05, 3:06PM CDT
bluebird bio, Inc. (Nasdaq: BLUE) announces that management will present at the Wedbush Life Science Conference on Wednesday, August 13, 2014 at 12.40 PM (EDT) at the Parker Meridian Hotel, New York, NY. Management will also present at the Canaccord Genuity Growth Conference on Thursday, August 14, 2014 at 2:00 PM (EDT) at the InterContinental Hotel, Boston, MA.
BLUE: 37.36 (+0.54)
5 Stocks Ready for Breakouts
at The Street - Mon Aug 04, 9:14AM CDT
These stocks are within range of triggering breakout trades.
BLUE: 37.36 (+0.54), TSLA: 235.34 (+4.87), ZPIN: 12.78 (-0.07), OVTI: 26.25 (-0.55), CDXS: 2.30 (+0.01), ATRO: 44.80 (+0.29)
Acquisition Agreements, Rejected Acquisition Tender Offers, Appointment, and Technical Updates - Research Reports on Pfizer, Gentiva, bluebird bio, Agios and AcelRx
PR Newswire - Wed Jul 23, 7:30AM CDT
Today, Analysts Review released its research reports regarding Pfizer Inc. (NYSE: PFE), Gentiva Health Services Inc. (NASDAQ: GTIV), bluebird bio, Inc. (NASDAQ: BLUE), Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) and AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/5013-100free.
ACRX: 6.85 (-0.05), BLUE: 37.36 (+0.54), PFE: 28.28 (+0.35), AGIO: 72.90 (+4.65), GTIV: 19.39 (unch)
3 Biotech Stocks Breaking Out on Big Volume
at The Street - Mon Jul 21, 8:10AM CDT
These biotech stocks rising on unusual volume are within range of triggering breakout trades.
BLUE: 37.36 (+0.54), RARE: 47.20 (+1.28), IMGN: 8.84 (-0.62)
bluebird bio, Inc. (BLUE) in Focus: Stock Surges 10.24% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Jul 21, 7:44AM CDT
bluebird bio, Inc. (BLUE) was a big mover last session, as the company saw its shares surge over 10% on the day.
BLUE: 37.36 (+0.54), BIIB: 326.77 (+15.36), BMRN: 74.71 (+3.71), ALXN: 174.48 (+6.28)
Buying Bluebird's Blockbuster Potential at a Discount
at The Street - Thu Jul 17, 9:33AM CDT
It's not often an investor gets the opportunity to buy a biotech stock with two blockbuster indications in the pipeline and major catalysts only months away at such a discount.
BLUE: 37.36 (+0.54)
